• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Kezar Life Sciences

acquisition merger arrows
Biotech

Kevin Tang uses control of Aurinia to finally take over Kezar

Aurinia, which named Kevin Tang as its new CEO last week, is acquiring Kezar after the latter company received promising feedback from the FDA.
Will Maddox Mar 30, 2026 10:53am
Deal

French biotech pens $128M deal for Kezar protein degrader work

Mar 12, 2026 9:00am
cancelled flights

Kezar plans layoffs after FDA axes meeting to discuss next trial

Oct 17, 2025 8:55am
green light shining in night

Kezar sees hepatitis hold lifted, mulls restarting lupus program

Jul 16, 2025 8:47am
FDA stop sign

FDA hits Kezar's zetomipzomib with 2nd clinical hold in 2 months

Nov 13, 2024 5:22am
Withdraw cancel rip up application

Kezar rejects Concentra buyout that 'undervalues' the biotech

Oct 17, 2024 9:10am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings